Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and myasthenia gravis are now recruiting.

Science that Strikes the Right Chord

We are applying our Cabaletta Approach to B cell Ablation (CABA®) platform to develop T cell therapies to transform the lives of patients with autoimmune diseases by aiming to deliver deep and durable – potentially curative – responses.

How We Target Autoimmune Disease

Why “Cabaletta"?

A “cabaletta” is a rapid, repetitive, and technically challenging section of an operatic aria, designed to showcase the skills of the lead singer. Analogously, Cabaletta Bio strives to achieve rapid and repetitive product development in a broad set of indications to maximize the opportunity for patients with autoimmune diseases to have a potentially curative option that may eliminate the need for long-term immunosuppression.

Composing Cell Therapy Approaches in Autoimmunity

Composing Cell Therapy Approaches in Autoimmunity

Building on the established success of T cell therapies in cancer and recent compelling clinical data on CD19-CAR T in autoimmunity, we are developing Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) to address a broad range of autoimmune diseases. CABA-201, our lead CARTA candidate, is an investigational fully human CD19 chimeric antigen receptor (CAR) T cell therapy with a 4-1BB co-stimulatory domain currently under development for systemic lupus erythematosus (SLE), myositis, systemic sclerosis, and generalized myasthenia gravis as well as other autoimmune diseases with high unmet need.


A Rapidly Expanding Collection of Targeted Cell Therapies

At Cabaletta, we are committed to transforming the treatment of autoimmune diseases by utilizing our innovative CABA® platform to develop cell therapy products with the aim of providing deep, durable and potentially curative responses for patients with autoimmune diseases. We are currently advancing CABA-201 in four RESET™ (REstoring SElf-Tolerance) Phase 1/2 trials in systemic lupus erythematosus, myositis, systemic sclerosis and generalized myasthenia gravis.

CABA-201 for Patients with Systemic Lupus Erythematosus

CABA-201 is designed to be given as a one-time infusion, with the potential to transiently, but fully, eliminate B cells, thus potentially enabling an “immune system reset” and durable remission in patients with systemic lupus erythematosus and lupus nephritis.

About CABA-201

CABA-201 for Patients with Myositis, Systemic Sclerosis & Generalized Myasthenia Gravis

Cabaletta is advancing CABA-201, a CD19-CAR T cell therapy candidate, in the RESETTM Phase 1/2 clinical trials in a broad range of autoimmune diseases across rheumatology and neurology.

View Our Pipeline

Putting Patients Center Stage

We’re on a mission to develop highly innovative and accessible cellular therapies with the potential to provide deep, durable, and potentially curative responses to patients by harnessing the power of the immune system. We aim to be champions for them.

Our Focus: Patients

Our Crew: Developing Novel Treatments for Patients with Autoimmune Diseases

We are a clinical-stage biotechnology company working to develop and launch potentially breakthrough engineered T cell therapies for patients with autoimmune diseases.

Email Alerts

Sign up for email alerts to stay informed and receive updates directly to your inbox.